fda glp-1 compounding crackdown news today New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Why the FDA Issued 30

Systemic Mast Cell Activation Disease: The Role of Molecular Genetic Alterations in Pathogenesis, Heritability and Diagnostics. Immunology, vol

Compared to the placebo (-4.0), liraglutide resulted in a greater change in BMI as a percentage of the 95th percentile (-14.0), and an estimated treatment difference of 10.0 (95% CI, 15.1 to 4.8) was observed

If there is serious trouble, like myxedema coma, you need to call emergency services right away

The two manufacturers of approved GLP-1s, Lilly and Novo Nordisk, have set up online platforms to bypass both compounding and traditional pharmacies, and Lilly has partnered with three telehealth services to provide access to obesity-trained doctors and registered dietitians